Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

OrderlyMeds, a provider of compounded versions of GLP-1 weight loss drugs, including Eli Lilly’s (NYSE:LLY) tirzepatide, said on Friday that a cease-and-desist letter sent by the pharma giant would ...

The Danish drugmaker has its hopes pinned on Ozempic (semaglutide), a weekly GLP-1 that will go head-to-head with Lilly’s Trulicity (dulaglutide), which has the same convenient dosing schedule.

Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Research reveals GLP-1 receptor agonists influence gut microbiome, enhancing metabolic health and offering anti-inflammatory ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

“This is important for patients with T2D, as progressive beta-cell dysfunction is a key factor in the disease’s development,” she highlighted. These mechanisms explain why GLP-1 analogs have ...

Prices of most of Lilly’s products are declining in the United States. Potential competition in the GLP-1 diabetes/obesity market is another headwind. Novo Nordisk has a strong presence in the ...

While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss ...